United Kingdom Artificial Intelligence in Drug Discovery Market Insight
The United Kingdom Artificial Intelligence in Drug Discovery Market is growing at an 26.01% CAGR, driven by rising R&D investments, faster drug development demand, and AI improving target identification and screening efficiency
United Kingdom Artificial Intelligence in Drug Discovery Market Insights Forecasts to 2035
- The United Kingdom Artificial Intelligence in Drug Discovery Market Size Was Estimated at USD 165.6 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 26.01% from 2025 to 2035
- The United Kingdom Artificial Intelligence in Drug Discovery Market Size is Expected to Reach USD 1671.2 Million by 2035
Notable Insights for United Kingdom Artificial Intelligence in Drug Discovery Market
- By technology, machine learning and deep learning dominated, accounting for approximately 60–65% share in 2024, driven by predictive analytics and automation capabilities.
- By application, target identification and lead optimization held approximately 55–60% share, due to increasing use of AI in early-stage drug discovery.
- Approximately 40–50% of pharmaceutical companies in the UK have integrated AI into drug discovery pipelines, reflecting rapid digital transformation.
- Around 65–75% of drug discovery timelines can be reduced using AI-based platforms, improving efficiency and lowering development costs.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Artificial Intelligence in Drug Discovery Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Artificial Intelligence in Drug Discovery Market
- Exscientia
- BenevolentAI
- Recursion Pharmaceuticals
- Schrödinger
- Insilico Medicine
- DeepMind
- AstraZeneca
- GlaxoSmithKline
- Others
Recent Developments:
- In January 2026: LIGAND-AI Consortium launched with €60 million funding, with University College London as a key partner, developing protein–ligand datasets to train AI models and accelerate drug discovery.
- In June 2025: OpenBind Consortium launched with £8 million funding to build a large open dataset of drug–protein interactions, enabling advanced AI models and strengthening the UK’s leadership in AI-driven drug discovery.
Market Segmentation:
United Kingdom Artificial Intelligence in Drug Discovery Market, By Technology
- Machine Learning
- Deep Learning
- Natural Language Processing
- Others
United Kingdom Artificial Intelligence in Drug Discovery Market, By Application
- Target Identification
- Lead Optimization
- Preclinical Testing
- Clinical Trials
- Others
United Kingdom Artificial Intelligence in Drug Discovery Market, By End User
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Research Institutes
United Kingdom Artificial Intelligence in Drug Discovery Market, By Deployment Mode Channel
- Cloud-Based
- On-Premise
Expert Views:
The UK Artificial Intelligence in Drug Discovery Market is expected to grow rapidly due to increasing demand for efficient, cost-effective drug development solutions. Experts emphasize that AI will transform drug discovery by improving accuracy, reducing timelines, and enabling precision medicine. Continued advancements in machine learning algorithms, data integration, and computational biology are anticipated to expand applications and drive significant market growth through 2035.